Open AccessDisease-modifying antirheumatic drugs improve cardiovascular autonomic neuropathy in psoriatic arthritis
Author(s) -
Ashit Syngle,
Inderjeet Verma,
Pawan Krishan,
Vijaita Syngle
Publication year - 2016
Publication title -
therapeutic advances in musculoskeletal disease
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.387
H-Index - 35
eISSN - 1759-7218
pISSN - 1759-720X
DOI - 10.1177/1759720x16635887
Subject(s) - medicine , psoriatic arthritis , disease , cardiology , heart rate , diaphragmatic breathing , arthritis , rheumatoid arthritis , blood pressure , pathology , alternative medicine
Cardiovascular autonomic neuropathy (CAN) is a significant risk predictor for sudden cardiac death in autoimmune rheumatic diseases. As yet, there is no therapeutic treatment of CAN in psoriatic arthritis (PsA). Even now, the impact of the most commonly employed disease-modifying antirheumatic drug (DMARD) therapy on CAN in PsA is not known. Hence, we investigated the impact of DMARDs on CAN in PsA.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom